Race-Develops-Improved-IV-Formulation-of-ZantreneDownload To discuss or comment on this announcement please visit our Investor Hub.

Race-Initiates-FTO-ALKBH5-Drug-Discovery-ProgramDownload To discuss or comment on this announcement please visit our Investor Hub.

Race Oncology CEO Phillip Lynch and CSO Dr Daniel Tillett present Race's June 2022 Quarterly Investor Briefing followed by a Q&A session. https://youtu.be/41g0MngwCrU

June-2022-Quarterly-Activity-ReportDownload